Compare Ralph Lauren Corp (RL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ralph Lauren Corp vs Zimmer Biomet Holdings Inc — how do they compare? Ralph Lauren Corp trades at $340.2 (market cap $20.69B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Ralph Lauren Corp is the larger of the two by market cap, and Ralph Lauren Corp pays the higher dividend (1.15%). Which is the better fit depends on your goals.
| RL | ZBH | |
|---|---|---|
Market Cap | $20.69B | $17.97B |
Sector | Consumer Cyclical | Health |
52-Week High | $414.25 | $104.26 |
52-Week Low | $302.89 | $79.58 |
Enterprise Value | $21.75B | $25.04B |
Dividend Yield | 1.15% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ralph Lauren (RL) trades at $347.23, down 1.13% on the day, with the stock showing bearish technical signals despite strong fundamentals. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.59 surpassing the $4.32 estimate. Revenue growth has accelerated from $6.2B in 2022 to $7.1B in 2025, while net income margins improved to 10.49%. Recent corporate developments include a new cancer center partnership in South Korea and ongoing AI investments to enhance customer experience.
The investment outlook remains positive with 66% analyst buy ratings and a $456.50 consensus price target representing 31% upside potential. However, the stock faces near-term technical pressure with bearish moving averages and faces execution risks in maintaining luxury brand positioning amid economic uncertainty. Strong profitability metrics including 37.54% ROE and improving cash flow generation support the long-term growth thesis.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
